

# Investigating the Impact of Donor Characteristics on Blood Product Quality

Elyn M. Rowe<sup>1</sup>, Owen Miller<sup>2</sup>, Jason Acker<sup>3</sup>, Mindy Goldman<sup>2,4</sup>, Dana V. Devine<sup>1</sup>

<sup>1</sup> Centre for Blood Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC

<sup>2</sup> Medical Affairs and Innovation, Canadian Blood Services, Ottawa ON

<sup>3</sup> Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton AB

<sup>4</sup> Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa ON




elyn.rowe@ubc.ca

## Background


### Changes to Canadian Blood Services (CBS) Donor Eligibility Criteria

In Canada, there is **no upper age limit** for blood donors and as of March 2021, most **individuals with diabetes are eligible** to donate blood.


Since blood products are not standardized like other therapeutics, we need to **ensure that older or diabetic donors provide blood products of similar quality to younger, healthier donors.**



### Storage Times and Resulting Lesions to Blood Products



### Effects of Aging and Glycemic Control on Blood Products




There is a need to assess the impact of these factors in the CBS donor population.

## Project Goals


- 1 Screen glycemic control in CBS donors and investigate its relationship with markers of product quality
- 2 Characterize blood products from diabetic donors and donors across the eligible age range to investigate differences in quality and storage performance

## Proposed Study Design




## Feasibility Data

### 1 Will platelet activation in retention samples (stored up to 5 days) reflect baseline platelet activation?




Although platelet activation levels are higher in EDTA tubes, they correlate well with routine citrate measures at baseline for up to 5 days stored at 4°C. This supports the feasibility of screening retention samples for platelet activation.

### 2 Are there enough donors with T1D in Vancouver for our study?



A total of 54 CBS donors in the Vancouver area over the past year have type 1 diabetes. With these numbers, we are confident in our ability to recruit N=8 from each sex into our study.

### 3 Can single-donor buffy coat platelet products be produced for storage studies?



A leukoreduced single-donor buffy coat platelet product with sufficient platelets for proposed experiments can be produced and stored. Smaller storage bags have comparable performance to regular platelet bags.

## Next Steps

- 4 Validation of red cell concentrate storage in transfer bags for Dr. Acker's additional assays over the storage period
- Begin flagging donor records for the receipt of retention samples in Aim 1 - pending CBS ethics approval
- Begin donor recruitment for whole blood donation study - pending CBS ethics approval

## Potential Impact

- Significant donor characteristic-dependent differences: Tailored storage times or applications of blood products based on donor characteristics
- No donor characteristic-dependent differences: Useful information for other blood services worldwide on the implications of expanding donor eligibility criteria

## With Support From



BLOOD PLASMA STEM CELLS ORGANS & TISSUES

